Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

USA News Group Commentary

Issued on behalf of BioVaxys Technology Corp.

VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catalysts. While five-year cancer survival rates are on an upward trend, the biotech sector is racing to meet these challenges head on with new treatments and safeguards against cancer, including recent developments from companies such as BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Moderna, Inc. (NASDAQ: MRNA), Boundless Bio, Inc. (NASDAQ: BOLD), ImmunityBio, Inc. (NASDAQ: IBRX), and MacroGenics, Inc. (NASDAQ: MGNX).